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(57) ABSTRACT 
Processes for preparing micronized particles comprising a 
poorly water soluble bioactive agent are provided. The pro 
cesses utilize a Superheated aqueous phase which can serve as 
the continuous phase of an emulsion. The Superheated aque 
ous phase can be used to melt poorly water soluble bioactive 
agents and/or matrix materials which them form molten drop 
lets dispersed within the Superheated aqueous phase. The size 
and size distribution of the molten droplets can be controlled 
using a variety of suitable methods. The molten droplets can 
then be cooled to form micronized particles comprising the 
poorly water soluble bioactive agent. If desired, the cooling 
rate can be selected to control the crystalline morphology of 
the resulting micronized particles. 
20 Claims, 3 Drawing Sheets 
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1. 
METHODS FOR FINE PARTICLE 
MANUFACTURE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Appli 
cation No. 61/865,782, filed Aug. 14, 2013, the disclosure of 
which is expressly incorporated herein by reference. 
BACKGROUND 
Recent advances in molecular biology have provided a vast 
array of potential new bioactive agents. However, it has been 
estimated that 60% of new bioactive agents exhibit limited 
water solubility. Formulating poorly water soluble bioactive 
agents into Suitable dosage forms poses a significant chal 
lenge due to difficulties in achieving adequate bioavailability 
of the bioactive agent in an aqueous biological system. 
In principle, the bioavailability of poorly water-soluble 
bioactive agents can be improved by decreasing the particle 
size of the bioactive agent. Various methods of reducing par 
ticle size have been explored, including milling, high pressure 
homogenization, spray drying, lyophilization of Solutions in 
water-organic solvent mixtures, and lyophilization of Solu 
tions in organic solvents. However, existing approaches for 
micronizing poorly water-soluble drugs have significant 
drawbacks. For example, many conventional approaches fail 
to provide precise control of particle size and/or particle size 
distribution. Other methods require the use of organic sol 
vents that can remain in the comminuted product. Improved 
methods of preparing micronized particles are needed to pro 
vide pharmaceutical formulations of poorly water soluble 
bioactive agents which can be readily prepared and which can 
improve the bioavailability of the poorly water soluble bio 
active agent. 
SUMMARY 
Processes for preparing micronized particles comprising a 
poorly water soluble bioactive agent are provided. Processes 
for preparing micronized particles comprising a poorly water 
soluble bioactive agent can comprise (a) heating an aqueous 
Suspension comprising the poorly water Soluble bioactive 
agent to a temperature of from about 100° C. to about 280°C. 
at a pressure of from greater than standard pressure to about 
1,000 psi to form a Superheated continuous phase comprising 
molten droplets of the poorly water soluble bioactive agent 
dispersed in Superheated water, and (b) cooling the molten 
droplets to form micronized particles comprising the poorly 
water soluble bioactive agent. Processes can further comprise 
reducing the size of the molten droplets while maintaining the 
Superheated continuous phase at a temperature of from about 
100° C. to about 280° C. and a pressure of from greater than 
standard pressure to about 1,000 psi. 
Also provided are processes for preparing micronized par 
ticles comprising a poorly water Soluble bioactive agent 
which comprise (a) melting the poorly water soluble bioac 
tive agent, (b) introducing the melted poorly water soluble 
bioactive agent into a Superheated aqueous phase heated to a 
temperature of from about 100° C. to about 280° C. at a 
pressure of from greater than standard pressure to about 1,000 
PSI to form a Superheated continuous phase comprising mol 
ten droplets of the poorly water soluble bioactive agent dis 
persed in Superheated water, and (c) cooling the molten drop 
lets to form micronized particles comprising the poorly water 













comprises a Superheated aqueous phase heated to a tempera 
ture ranging from the melting point of the poorly water 
soluble bioactive agent to 20° C. higher than the melting point 
of the poorly water soluble bioactive agent (e.g., heated to a 
temperature ranging from the melting point of the poorly 
water soluble bioactive agent to 10°C. higher than the melt 
ing point of the poorly water soluble bioactive agent). 
Introducing the melted poorly water soluble bioactive 
agent into the Superheated aqueous phase can comprise 
injecting droplets of the melted poorly water soluble bioac 
tive agent into the Superheated aqueous phase. Injecting drop 
lets of the melted poorly water soluble bioactive agent into the 
Superheated aqueous phase can comprise spraying the melted 
poorly water soluble bioactive agent into the superheated 
aqueous phase. Injecting droplets of the melted poorly water 
soluble bioactive agent into the Superheated aqueous phase 
can comprise extruding the melted poorly water soluble bio 
active agent into the Superheated aqueous phase. For 
example, the melted poorly water Soluble bioactive agent can 
be extruded into the Superheated aqueous phase through a 
microporous membrane (i.e., membrane emulsification). In 
certain embodiments, the Superheated aqueous phase is flow 
ing orthogonally to the Surface of the microporous membrane 
during extrusion of the melted poorly water soluble bioactive 
agent into the Superheated aqueous phase (i.e., cross-flow 
membrane emulsification). 
In variations of the processes described above, a matrix 
material and a poorly water Soluble bioactive agent are added 
to the aqueous phase. These processes can be used to form 
micronized particles comprising a mixture of a matrix mate 
rial and a poorly water soluble bioactive agent. Thus, also 
provided are processes for preparing micronized particles 
comprising a poorly water soluble bioactive agent that can 
comprise (a) heating an aqueous Suspension comprising a 
matrix material and the poorly water soluble bioactive agent 
to a temperature of from about 100° C. to about 280° C. at a 
pressure of from greater than standard pressure to about 1,000 
PSI to form a Superheated continuous phase comprising mol 
ten droplets of the matrix material dispersed in superheated 
water, and (b) cooling the molten droplets to form micronized 
particles comprising the matrix material and the poorly water 
soluble bioactive agent. In certain embodiments, step (a) 
comprises heating the aqueous Suspension to a temperature 
ranging from the melting point of the matrix material to 10° 
C. higher than the melting point of the matrix material. 
Any suitable matrix material can be used. The matrix mate 
rial can be, for example, a polymer, wax, or lipid which 
provides for the controlled release of the poorly water soluble 
bioactive agent. The poorly water Soluble bioactive agent can 
have a higher melting point than the matrix material. The 
aqueous Suspension can be heated to a temperature greater 
than the melting point of both the matrix material and the 
poorly water Soluble bioactive agent. Alternatively, the aque 
ous Suspension can be heated to a temperature ranging from 
the melting point of the matrix material to less than the melt 
ing point of the poorly water soluble bioactive agent. In these 
embodiments, molten droplets of the matrix material can 
serve as a solvent in which the poorly water soluble bioactive 
agent is dissolved or dispersed. In certain cases, the poorly 
water soluble bioactive agent dissolves in the molten droplets 
of the matrix material, and step (b) comprises cooling the 
molten droplets to form micronized particles comprising the 
first poorly water soluble bioactive agent and the second 
poorly water Soluble bioactive agent. In other cases, the 
poorly water soluble bioactive agent becomes dispersed in the 
molten droplets of the matrix material, and step (b) comprises 
cooling the molten droplets to form micronized particles 
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comprising the first poorly water soluble bioactive agent and 
the second poorly water Soluble bioactive agent. 
Also provided are micronized particles formed using the 
processes described herein, as well as pharmaceutical formu 
lations which include the micronized particles. 
DESCRIPTION OF DRAWINGS 
FIG. 1 is plot of the particle size distribution of populations 
of micronized particles prepared from ibuprofen. 
FIG. 2 is a differential scanning calorimetry (DSC) curve 
of a 2:3 physical mixture of ciprofloxacin/ibuprofen. 
FIG.3 is plot of the particle size distribution of populations 
of micronized particles prepared from a 2:3 physical mixture 
of ciprofloxacin/ibuprofen. 
DETAILED DESCRIPTION 
Processes for preparing micronized particles comprising a 
poorly water soluble bioactive agent are provided. The pro 
cesses utilize a Superheated aqueous phase (i.e., an aqueous 
liquid under pressure at a temperature ranging from the aque 
ous liquid’s boiling point to the aqueous liquid’s critical 
temperature, such as liquid water underpressure at a tempera 
ture ranging from about 100° C. to about 374°C.) which can 
serve as the continuous phase of an emulsion. The Super 
heated aqueous phase can be used to melt poorly water 
soluble bioactive agents and/or matrix materials which them 
form molten droplets dispersed within the Superheated aque 
ous phase. The size and size distribution of the molten drop 
lets can be controlled using a variety of suitable methods. The 
molten droplets can then be cooled to form micronized par 
ticles comprising the poorly water Soluble bioactive agent. If 
desired, the cooling rate can be selected to control the crys 
talline morphology of the resulting micronized particles. 
Processes for preparing micronized particles comprising a 
poorly water Soluble bioactive agent can comprise (a) heating 
an aqueous Suspension comprising the poorly water soluble 
bioactive agent to a temperature of from about 100° C. to 
about 280° C. at a pressure of from greater than standard 
pressure to about 1,000 psi to form a superheated continuous 
phase comprising molten droplets of the poorly water soluble 
bioactive agent dispersed in Superheated water, and (b) cool 
ing the molten droplets to form micronized particles compris 
ing the poorly water soluble bioactive agent. Processes can 
further comprise reducing the size of the molten droplets 
while maintaining the Superheated continuous phase at a tem 
perature of from about 100° C. to about 280° C. and a pressure 
of from greater than standard pressure to about 1,000 psi. 
The temperature to which the aqueous Suspension is heated 
can be selected in view of a number of factors, including the 
identity of the poorly water soluble bioactive agent (e.g., the 
melting point of the poorly water soluble bioactive agent, the 
thermal stability of the poorly water soluble bioactive agent, 
etc.), processing parameters such as the method of reducing 
the size of the molten droplets, the desired average particle 
size of the resulting micronized particles, the desired particle 
size distribution of the resulting micronized particles. 
The aqueous Suspension in step (a) can be heated to a 
temperature of at least about 100°C. (e.g., at least about 110° 
C., at least about 120°C., at least about 130°C., at least about 
140°C., at least about 150° C., at least about 160° C., at least 
about 170° C., at least about 180°C., at least about 190° C., at 
least about 200° C., at least about 210°C., at least about 220° 
C., at least about 230°C., at least about 240°C., at least about 
250° C., at least about 260° C., or at least about 270° C.). In 













a temperature about 280° C. or less (e.g., about 270° C. or 
less, about 260° C. or less, about 250° C. or less, about 240° 
C. or less, about 230° C. or less, about 220° C. or less, about 
210°C. or less, about 200° C. or less, about 190° C. or less, 
about 180° C. or less, about 170° C. or less, about 160° C. or 
less, about 150° C. or less, about 140°C. or less, about 130° 
C. or less, about 120° C. or less, or about 110° C. or less). 
The aqueous suspension in step (a) can be heated to a 
temperature ranging from any of the minimum temperatures 
described above to any of the maximum temperatures 
described above. For example, the aqueous Suspension in step 
(a) can be heated to a temperature ranging from about 100° C. 
to about 280° C. (e.g., from about 100° C. to about 245° C., 
from about 100° C. to about 200° C., or from about 150° C. to 
about 250° C.). 
In certain embodiments, the temperature to which the 
aqueous Suspension is heated can be selected in view of the 
identity of the poorly water soluble bioactive agent, process 
ing parameters such as the method of reducing the size of the 
molten droplets, the desired average particle size of the result 
ing micronized particles, the desired particle size distribution 
of the resulting micronized particles. As the aqueous Suspen 
sion is heated above the melting point of the poorly water 
soluble bioactive agent, both the viscosity of the molten 
poorly water Soluble bioactive agent and the Surface tension 
of the aqueous phase are decreased. As a result, the size of the 
molten droplets (and thus the size of the resultant micronized 
particles) can be more readily reduced in size (i.e., less energy 
can be introduced to reduce the size of the molten droplets). 
The aqueous Suspension in step (a) can be heated to a tem 
perature greater than the melting point of the poorly water 
soluble bioactive agent (e.g., at least about 5°C., at least about 
10° C., at least about 15° C., at least about 20° C., at least 
about 25°C., at least about 30° C., at least about 35° C., at 
least about 40°C., at least about 45° C., at least about 50° C., 
at least about 55° C., at least about 60°C., at least about 65° 
C., at least about 70° C., at least about 75° C., at least about 
80° C., at least about 85°C., at least about 90° C., or at least 
about 95°C. higher than the melting point of the poorly water 
soluble bioactive agent). The aqueous Suspension in step (a) 
can be heated to a temperature of about 100° C. or less above 
the melting point of the poorly water soluble bioactive agent 
(e.g. about 95°C. or less, about 90° C. or less, about 85°C. or 
less, about 80°C. or less, about 75° C. or less, about 70° C. or 
less, about 65° C. or less, about 60° C. or less, about 55° C. or 
less, about 50° C. or less, about 45° C. or less, about 40°C. or 
less, about 35° C. or less, about 30°C. or less, about 25°C. or 
less, about 20°C. or less, about 15° C. or less, about 10°C. or 
less, or about 5° C. or less above the melting point of the 
poorly water soluble bioactive agent). 
The temperature to which the aqueous Suspension is heated 
can range from any of the minimum temperatures described 
above to any of the maximum temperatures described above. 
For example, the temperature to which the aqueous Suspen 
sion is heated can range from the melting point of the poorly 
water soluble bioactive agent to about 100° C. higher than the 
melting point of the poorly water soluble bioactive agent 
(e.g., from about 5°C. higher the melting point of the poorly 
water soluble bioactive agent to about 100° C. higher than the 
melting point of the poorly water soluble bioactive agent, 
from about 5° C. higher the melting point of the poorly water 
soluble bioactive agent to about 50° C. higher than the melt 
ing point of the poorly water Soluble bioactive agent, or from 
the melting point of the poorly water soluble bioactive agent 
to about 10° C. higher than the melting point of the poorly 
water soluble bioactive agent). 
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The aqueous Suspension can be heated under a pressure 
greater than standard pressure (i.e., about 14.7 psi). During 
heating, the aqueous Suspension can be contained in a closed 
vessel or apparatus at a pressure higher than ambient pres 
Sure. The aqueous Suspension can be contained in a pressur- 5 
ized closed system such as a stainless Steel vessel or bomb 
which is configured to permit heating of the Suspension and 
optionally reduction of the size of the molten droplets in the 
Superheated continuous phase. The vessel can also be con 
nected through Suitable piping and valves to an apparatus to 10 
reduce the size of the molten droplets in the superheated 
continuous phase. The aqueous Suspension can be heated 
under a pressure of at least about 25 psi, at least about 50 psi, 
at least about 75 psi, at least about 100 psi, at least about 200 
psi, at least about 250 psi, at least about 300 psi, at least about 15 
400 psi, at least about 500 psi, at least about 600 psi, at least 
about 700psi, at least about 750 psi, at least about 800 psi, or 
at least about 900 psi. The aqueous suspension can be heated 
under a pressure of about 1000 psi or less (e.g., about 900 psi 
or less, about 800 psi or less, about 750 psi or less, about 700 20 
psi or less, about 600 psi or less, about 500 psi or less, about 
400 psi or less, about 300 psi or less, about 250 psi or less, 
about 200 psi or less, about 100 psi or less, about 75 psi or 
less, about 50 psi or less, or about 25 psi or less). 
The aqueous Suspension can be heated under a pressure 25 
ranging from any of the minimum pressures described above 
to any of the maximum pressured described above. For 
example, the aqueous Suspension can be heated under a pres 
Sure ranging from greater than standard pressure to about 
1000 psi (e.g., from greater than standard pressure to about 30 
500 psi, or from about 50 psi to about 500 psi). 
The poorly water soluble bioactive agent can be any physi 
ologically or pharmacologically active Substances that acts 
locally or systemically in the body. The bioactive agent can be 
a Substance used for the treatment (e.g., a therapeutic agent), 35 
prevention (e.g., a prophylactic agent), diagnosis (e.g., a diag 
nostic agent), cure or mitigation of disease or illness, a Sub 
stance which affects the structure or function of the body 
(e.g., a nutritional agent), or a pro-drug which becomes bio 
logically active or more active after they have been placed in 40 
a predetermined physiological environment. Examples of 
Suitable bioactive agents include anti-neoplastic agents, 
anthelmintics agents, antibiotics, anticoagulants, antidepres 
sants, antidiabetic agents, antiepileptics, antihistamines, anti 
hypertensive agents, antimuscarinic agents, antimycobacte- 45 
rial agents, immunosuppressants, antithyroid agents, 
antiviral agents, anxiolytic sedatives, astringents, beta 
adrenoceptor blocking agents, beta-adrenergic agonists, car 
diac inotropic agents, contrast media, corticosteroids, cough 
Suppressants, diagnostic agents, diagnostic imaging agents, 50 
diuretics, dopaminergics, haemostatics, immunological 
agents, lipid regulating agents, muscle relaxants, parasym 
pathomimetics, parathyroid calcitonin, biphosphonates, pro 
tease inhibitors, prostaglandins, radiopharmaceuticals, sex 
hormones, steroids, anti-allergic agents, stimulants, sym- 55 
pathomimetics, thyroid agents, vasodilators and Xanthines, 
disulfide compounds, antibacterials, antivirals, nonsteroidal 
anti-inflammatory drugs, analgesics, anticoagulants, anticon 
Vulsants, antiemetics, antifungals, anti-inflammatory agents, 
antiprotozoals, antipsychotics, cardioprotective agents, cyto- 60 
protective agents, antiarrhythmics, hormones, immunostimu 
lating agents, lipid-lowering agents, platelet aggregation 
inhibitors, agents for treating prostatic hyperplasia, agents for 
treatment of rheumatic disease, vascular agents, nutrients, 
Vitamins, imaging agents, contrast agents, and combinations 65 
thereof. A detailed description of these and other suitable 
bioactive agents may be found in Remington's Pharmaceuti 
6 
cal Sciences, 18th edition, 1990, Mack Publishing Co. Phila 
delphia, Pa. which is hereby incorporated by reference. 
The poorly water soluble bioactive agent can have a solu 
bility in water at 25°C. of about 10.0 mg/mL or less (e.g., 
about 9.5 mg/mL or less, about 9.0 mg/mL or less, about 8.5 
mg/mL or less, about 8.0 mg/mL or less, about 7.5 mg/mL or 
less, about 7.0 mg/mL or less, about 6.5 mg/mL or less, about 
6.0 mg/mL or less, about 5.5 mg/mL or less, about 5.0 mg/mL 
or less, about 4.5 mg/mL or less, about 4.0 mg/mL or less, 
about 3.5 mg/mL or less, about 3.0 mg/mL or less, about 2.5 
mg/mL or less, about 2.0 mg/mL or less, about 1.5 mg/mL or 
less, about 1.0 mg/mL or less, about 0.75 mg/mL or less, 
about 0.50 mg/mL or less, about 0.25 mg/mL or less, about 
0.10 mg/mL or less, or less). In some cases, the bioactive 
agent is substantially insoluble in water (i.e., the bioactive 
agent has a solubility in water at 25° C. of less than 0.05 
mg/mL). 
In some embodiments, the poorly water soluble bioactive 
agent can exhibit a solubility described above in water at 
physiological pH (i.e., a pH ranging from 6.5 to 7.4). In other 
embodiments, the poorly water soluble bioactive agent com 
prises a bioactive agent which exhibits pH-dependent solu 
bility. For example, the poorly water soluble bioactive agent 
can be a bioactive agent which exhibit a solubility higher than 
10.0 mg/mL in water at 25°C. and at physiological pH, but 
exhibits a solubility described above in water at 25°C. and at 
a pH lower or higher than physiological pH. In these embodi 
ments, the pH of the aqueous phase can be adjusted by addi 
tion of a pH modifier (e.g., an acid or base). Such that the 
bioactive agent exhibits a solubility described above in the 
aqueous phase during the course of the processes described 
herein. 
In some embodiments, the poorly water soluble bioactive 
agent can be an amphiphilic bioactive agent. Amphiphilic 
compounds are molecules which possess both a hydrophilic 
and a hydrophobic moiety. For example, ibuprofen is 
amphiphilic when ionized. In these embodiments, the pH of 
the aqueous phase can be adjusted by addition of a pH modi 
fier (e.g., an acid or base) to ionize at least a portion of the 
bioactive agent, such that the bioactive agent is amphiphilic. 
When present, the amphiphilic active agent can reduce the 
interfacial tension between the aqueous phase and the molten 
droplets, stabilizing the dispersion. 
The poorly water soluble bioactive agent can be an agent 
can be a bioactive agent which melts without decomposition. 
In some embodiments, the poorly water soluble bioactive 
agent can have a melting point of at least about 25°C. (e.g., at 
least about 30°C., at least about 35°C., at least about 40°C., 
at least about 45° C., at least about 50° C., at least about 55° 
C., at least about 60° C., at least about 65° C., at least about 
70° C., at least about 75° C., at least about 80° C., at least 
about 85°C., at least about 90° C., at least about 95°C., at 
least about 100° C., at least about 105°C., at least about 110° 
C., at least about 115°C., at least about 120°C., at least about 
125°C., at least about 130°C., at least about 135°C., at least 
about 140°C., at least about 145°C., at least about 150°C., at 
least about 155° C., at least about 160° C., at least about 165° 
C., at least about 170° C., at least about 175°C., at least about 
180°C., at least about 185°C., at least about 190° C., at least 
about 195°C., at least about 200°C., at least about 205°C., at 
least about 210°C., at least about 215°C., at least about 220° 
C., at least about 225°C., at least about 230°C., at least about 
235°C., at least about 240°C., at least about 24.5°C., at least 
about 250° C., at least about 255°C., at least about 260°C., at 
least about 265° C., at least about 270° C., or at least about 
275° C.). In some embodiments, the poorly water soluble 
bioactive agent can have a melting point of about 280° C. or 
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less (e.g., about 275° C. or less, about 270° C. or less, about 
265° C. or less, about 260° C. or less, about 255° C. or less, 
about 250° C. or less, about 245° C. or less, about 240° C. or 
less, about 235° C. or less, about 230° C. or less, about 225° 
C. or less, about 220° C. or less, about 215° C. or less, about 
210°C. or less, about 205° C. or less, about 200° C. or less, 
about 195°C. or less, about 190° C. or less, about 185°C. or 
less, about 180° C. or less, about 175° C. or less, about 170° 
C. or less, about 165° C. or less, about 160° C. or less, about 
155° C. or less, about 150° C. or less, about 145° C. or less, 
about 140°C. or less, about 135° C. or less, about 130° C. or 
less, about 125° C. or less, about 120° C. or less, about 115° 
C. or less, about 110° C. or less, about 105° C. or less, about 
100° C. or less, about 95°C. or less, about 90° C. or less, about 
85°C. or less, about 80°C. or less, about 75° C. or less, about 
70° C. or less, about 65° C. or less, about 60° C. or less, about 
55° C. or less, about 50° C. or less, about 45° C. or less, about 
40° C. or less, about 35° C. or less, or about 30° C. or less). 
The poorly water soluble bioactive agent can have a melt 
ing point ranging from any of the minimum values described 
above to any of the maximum values described above. For 
example, the poorly water Soluble bioactive agent can have a 
melting point ranging from about 25° C. to about 280° C. 
(e.g., from about 50° C. to about 280°C., or from about 100° 
C. to about 280° C.). 
Examples of poorly water soluble bioactive agents include 
albendazole (m.p. 208-210° C.), albendazole sulfoxide, 
alfaxalone (m.p. 172-174° C.), acetyl digoxin, acyclovirana 
logs melting at or below 280° C., alprostadil, aminofostin, 
anipamil, antithrombin III, atenolol (m.p. 146-148° C.), azi 
dothymidine, bacitracin zinc, beclobrate (m.p. 200-204°C.), 
beclomethasone (m.p. 117-120° C.), belomycin, benzocaine 
(m.p. 88-90°C.) and derivatives, beta carotene (m.p. 183°C.), 
beta endorphin, beta interferon, betaxolol HCl, bezafibrate 
(m.p. 186°C.), binovum, biperiden (m.p. 112-116° C.), bri 
monidine tartrate, brinzolamide, bromazepam (m.p. 
237-238°C.), bromfenac, bromocryptine, bucindolol, buflo 
medil (m.p. 192-193° C.), bupivacaine (m.p. 107-108° C.), 
busulfan (m.p. 114-118°C.), cadralazine (m.p. 160-162°C.), 
camptothesin (m.p. 264-267 and 275° C.), canthaxanthin 
(m.p. 217°C.), captopril (m.p. 103-104°C.), carbamazepine 
(m.p. 190-193° C.), carboprost, carvedilol (m.p. 115° C.), 
cefalexin, cefalotin, cefamandole (m.p. 190° C.), cefazedone, 
cefluoroxime, cefinenoxime, cefoperazone (m.p. 169-171° 
C.), cefotaxime, cefoxitin (m.p. 149-150° C.), cefsulodin 
(m.p. 175° C.), ceftizoxime, chlorambucil (m.p. 64-66° C.), 
chloramphenicol, chromoglycinic acid, ciclonicate (m.p. 
127-128° C.), ciglitaZone, ciprofloxacin, clonidine (m.p. 
130° C.), cortexolone, corticosterone (m.p. 180-182° C.), 
cortisol (m.p. 212-220° C.), cortisone (m.p. 220-224° C.), 
cyclophosphamide (m.p. 41-45° C.), cyclosporins, such as 
cyclosporin A (m.p. 148-151°C.), cytarabine (m.p. 212-213 
C.), desocryptin, desogestrel (m.p. 109-110°C.), dexametha 
Sone, as well as dexamethasone esters such as the acetate ester 
(m.p. 238-240°C.), dezocine, diazepam (m.p. 125-126°C.), 
diclofenac, dideoxyadenosine (m.p. 160-163°C.), dideoxyi 
nosine, difluprednate, digitoxin (m.p. 256-257°C.), digoxin, 
dihydroergotamine (m.p. 239° C.), dihydroergotoxin, dilt 
iazem (m.p. 207-212°C.), dopamine antagonists, doxorubi 
cin (m.p. 229-231°C.), econazole (m.p. 87°C.), endralazine 
(m.p. 185-188°C.), enkephalin, enalapril (m.p. 143-145° C.), 
epoprostenol, erythromycin, estradiol (m.p. 173-179° C.), 
estramustine (m.p. 104-105° C.), etofibrate (m.p. 100° C.), 
etoposide (m.p. 236-251°C.), factorix, factor viii, felbamate 
(m.p. 151-152°C.), fenbendazole (m.p. 233°C.), fenofibrate 
(m.p. 79-82°C.), flunarizin (m.p. 252°C.), flurbiprofen (m.p. 













282-283°C.), flurazepam (m.p. 77-82°C.), fosfomycin (m.p. 
approx. 94° C.), fosmidomycin, furosemide (m.p. 206° C.), 
gallopamil, gamma interferon, ganciclovir, gentamicin (m.p. 
102-108°C.), gepefrine (m.p. 155-158°C.), gliclazide (m.p. 
180-182 C.), glipizide (m.p. 208-209° C.), griseofulvin 
(m.p. 220°C.), haptoglobulin, hepatitis B vaccine, hydrala 
zine (m.p. 172-173° C.), hydrochlorothiazide (m.p. 273-275° 
C.), hydrocortisone (m.p. 212-220° C.), ibuprofen (m.p. 
75-77° C.), ibuproxam (m.p. 119-121° C.), indinavir, 
indomethacin (m.p. 155° C.), iodinated aromatic X-ray con 
trast agents melting below 275° C. Such as iodamide (m.p. 
255-257°C.), ipratropium bromide (m.p. 230-232C.), keto 
conazole (m.p. 146°C.), ketoprofen (m.p. 94° C.), ketorolac, 
ketotifen (m.p. 152-153°C.), ketotifen fumarate (m.p. 192 
C.), K-strophanthin (m.p. approx. 175° C.), labetalol, lacto 
bacillus vaccine, Levocabastine HCl, levofloxacin, lidocaine 
(m.p. 68-69°C.), lidoflazin (m.p. 159-161° C.), lisuride (m.p. 
186° C.), lisuride hydrogen maleate (m.p. 200° C.), 
lorazepam (m.p. 166-168° C.), loteprednol HCl, lovastatin, 
mefenamic acid (m.p. 230-231° C.), melphalan (m.p. 182 
183° C.), memantin, mesulergin, metergoline (m.p. 146-149° 
C.), methotrexate (m.p. 185-204°C.), methyl digoxin (m.p. 
227-231° C.), methylprednisolone (m.p. 228-237° C.), met 
ronidazole (m.p. 158-160° C.), metisoprenol, metipranolol 
(m.p. 105-107° C.), metkephamide metolazone (m.p. 253 
259 C.), metoprolol, metoprolol tartrate, miconazole (m.p. 
135°C.), miconazole nitrate (m.p. 170 and 185°C.), minoxi 
dil (m.p. 248° C.), misonidazol, molsidomin, nadolol (m.p. 
124-136° C.), nafiverine (m.p. 220-221° C.), nafazatrom, 
naproxen (m.p. 155° C.), natural insulins, nepafenac, nesapi 
dil, neomycin, nicardipine (m.p. 168-170° C.), nicorandil 
(m.p. 92-93° C.), nifedipine (m.p. 172-174° C.), niludipin, 
nimodipine, nitrazepam (m.p. 224-226° C.), nitrendipine, 
nitrocamptothesin, 9-nitrocamptothesin, oxazepam (m.p. 
205-206° C.), oxprenolol (m.p. 78-80° C.), oxytetracycline 
(m.p. 181-182°C.), penicillins such as penicillin G beneth 
amine (m.p. 147-147 C.), penecillin 0 (m.p. 79-81° C.), 
phenylbutaZone (m.p. 105°C.), picotamide, pilocarpine, pin 
dolol (m.p. 171-173° C.), piposulfan (m.p. 175-177° C.), 
piretanide (m.p. 225-227°C.), piribedil (m.p. 98°C.), piroxi 
cam (m.p. 198-200° C.), pirprofen (m.p. 98-100° C.), plas 
minogenic activator, polymyxin b, prednisone, prednisolone 
(m.p. 240-241° C.), prednisone (m.p. 233-235° C.), preg 
nenolone (m.p. 193°C.), procarbacin, procaterol, progester 
one (m.p. 121°C.), proinsulin, propafenone, propanolol, pro 
pentofyllin, propofol, propranolol (m.p. 96° C.), rifapentin, 
rimexolone, simvastatin, semi-synthetic insulins, Sobrerol 
(m.p. 130° C.). Somastotine and its derivatives, somatropin, 
stilamine, sulfinalol whose hydrochloride melts at 175°C., 
sulfinpyrazone (m.p. 136-137° C.), Suloctidil (m.p. 62-63 
C.), Suprofen (m.p. 124°C.), Sulproston, synthetic insulins, 
talinolol (m.p. 142-144° C.), taxol, taxotere, testosterone 
(m.p. 155° C.), testosterone propionate (m.p. 118-122°C.), 
testosterone undecanoate, tetracane HI (m.p. approx. 150° 
C.), tiaramide (HC1 m.p. 159-161° C.), timolol, tolmetin 
(m.p. 155-157°C.), tranilast (m.p. 211-213°C.), travoprost, 
triquilar, tromantadine (HC1 m.p. 157-158°C.), urokinase, 
valium (m.p. 125-126° C.), Verapamil (m.p. 243-246° C.), 
Vidarabine, Vidarabine phosphate sodium salt, vinblastine 
(m.p. 211-216°C.), vinburin, Vincamine (m.p. 232-233°C.), 
Vincristine (m.p. 218-220°C.), vindesine (m.p. 230-232C.), 
vinpocetine (m.p. 147-153°C.), vitamin A (m.p. 62-64°C.), 
vitamin E succinate (m.p. 76-78° C.), and x-ray contrast 
agents. 
In certain embodiments, the poorly water soluble bioactive 
agent comprises an anti-neoplastic agent, an anti-inflamma 
tory agent, or combinations thereof. In some embodiments, 
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the poorly water soluble bioactive agent comprises a bioac 
tive agent for the treatment, prevention, or diagnosis of a 
pulmonary disease or disorder, such as asthma or cystic fibro 
sis. For example, the poorly water Soluble bioactive agent can 
comprise a bronchodilator, a vasodilator, a phosphodiesterase 
inhibitor, an endothelin receptor antagonist, an anti-inflam 
matory drugs, an anti-infective agent, a mucus-degrading 
agent, or combinations thereof. In some embodiments, the 
poorly water soluble bioactive agent comprises a bioactive 
agent for the treatment, prevention, or diagnosis of an ocular 
disease or disorder. Such as age-related macular degeneration. 
The amount of poorly water soluble bioactive agent present 
in the aqueous Suspension can be varied. In some embodi 
ments, the poorly water Soluble bioactive agent is at least 
about 5% by weight of the aqueous Suspension, based on the 
total weight of the aqueous Suspension (e.g., at least about 
10% by weight, at least about 15% by weight, at least about 
20% by weight, at least about 25% by weight, at least about 
30% by weight, at least about 35% by weight, at least about 
40% by weight, at least about 45% by weight, at least about 
50% by weight, at least about 55% by weight, at least about 
60% by weight, at least about 65% by weight, at least about 
70% by weight, or at least about 75% by weight). In some 
embodiments, the poorly water Soluble bioactive agent is 
about 80% or less by weight of the aqueous suspension, based 
on the total weight of the aqueous Suspension (e.g., about 
75% or less by weight, about 70% or less by weight, about 
65% or less by weight, about 60% or less by weight, about 
55% or less by weight, about 50% or less by weight, about 
45% or less by weight, about 40% or less by weight, about 
35% or less by weight, about 30% or less by weight, about 
25% or less by weight, about 20% or less by weight, about 
15% or less by weight, or about 10% or less by weight). 
The amount of poorly water soluble bioactive agent present 
in the aqueous Suspension can vary from any of the minimum 
described above to any of the maximum values described 
above. For example, the poorly water soluble bioactive agent 
can be present in an amount ranging from about 5% by weight 
to about 80% by weight of the aqueous suspension, based on 
the total weight of the aqueous Suspension (e.g., from about 
5% by weight to about 50% by weight, or from about 5% by 
weight to about 30% by weight). 
The molten droplets of the poorly water soluble bioactive 
agent can be cooled using a variety of Suitable methods. The 
cooling rate can be selected in order to influence the crystal 
line form of the poorly water soluble bioactive agent. For 
example, the molten droplets can be cooled slowly to select 
for crystalline micronized particles formed from a thermody 
namically stable polymorph of the poorly water soluble bio 
active agent. Alternatively, the molten droplets can be rapidly 
cooled to select for amorphous micronized particles formed 
from a poorly water soluble bioactive agent. 
In some embodiments, the molten droplets are cooled 
instantly (i.e., flash frozen, for example, using a cryogenic 
liquid Such as liquid nitrogen). In certain embodiments, the 
molten droplets are cooled by spraying the aqueous continu 
ous phase. The aqueous continuous phase can be sprayed into 
a gas or liquid. In some embodiments, the molten droplets are 
cooled at a rate of at least about 0.1° C./minute (e.g., at least 
about 0.5° C./minute, at least about 1° C./minute, at least 
about 2°C./minute, at least about 3°C./minute, at least about 
4° C./minute, at least about 5° C./minute, at least about 6° 
C./minute, at least about 7° C./minute, at least about 8° 
C./minute, at least about 9° C./minute, at least about 10° 
C./minute, at least about 15° C./minute, at least about 20° 
C./minute, at least about 25°C/minute, at least about 30° 














C./minute, at least about 45° C./minute, at least about 50° 
C./minute, at least about 75° C./minute, at least about 100° 
C./minute, at least about 125°C/minute, at least about 150° 
C./minute, or at least about 175°C/minute). In some embodi 
ments, the molten droplets are cooled at a rate of about 200° 
C./minute or less (e.g., about 175°C/minute or less, about 
150° C./minute or less, about 125° C./minute or less, about 
100°C/minute or less, about 75°C/minute or less, about 50° 
C./minute or less, about 45° C./minute or less, about 40° 
C./minute or less, about 35° C./minute or less, about 30° 
C./minute or less, about 25° C./minute or less, about 20° 
C./minute or less, about 15° C./minute or less, about 10° 
C./minute or less, about 9° C./minute or less, about 8° 
C./minute or less, about 7° C./minute or less, about 6° 
C./minute or less, about 5° C./minute or less, about 4° 
C./minute or less, about 3° C./minute or less, about 2 
C./minute or less, about 1° C./minute or less, or about 0.5° 
C./minute or less). The molten droplets are cooled at a rate 
ranging from any of the minimum rates described above to 
any of the maximum rates described above. 
The molten droplets can be cooled at a linear or non-linear 
cooling rate. When the molten droplets are cooled at a linear 
cooling rate, the cooling rates described above can be cooling 
rates for a portion or an entirety of the cooling process. When 
the molten droplets are cooled at a non-linear cooling rate, the 
cooling rates described above can be average cooling rates for 
the cooling process. 
In some embodiments, processes can further comprise 
reducing the size of the molten droplets while maintaining the 
Superheated continuous phase at a temperature of from about 
100° C. to about 280° C. and a pressure of from greater than 
standard pressure to about 1,000 psi. Suitable methods for 
reducing the size of the molten droplets can be selected in 
view of a number of factors, including the desired average 
particle size of the resulting micronized particles, the desired 
particle size distribution of the resulting Methods of reducing 
the size of the molten droplets can include stirring, shaking 
(including vibrational resonance mixing), agitating, Vortex 
ing (including crossflow Vortex mixing), mixing, Sonication 
(including acoustic resonance mixing), microfluidization, 
extrusion (e.g., membrane emulsification), spraying, injec 
tion, alteration of head pressure (e.g., rapidly decreasing head 
pressure over the continuous phase), or combinations thereof. 
In some embodiments, reducing the size of the molten 
droplets comprises a low energy process. Low energy pro 
cesses reduce the size of the molten droplets while imparting 
a low amount of mechanical energy to the continuous phase. 
In some embodiments, the amount of energy imparted to the 
continuous phase by the size reduction process is at least 
about 0.0005J (e.g., at least about 0.001 J, at least about 0.005 
J., at least about 0.01 J., at least about 0.05 J. at least about 0.1 
J., at least about 0.5 J, at least about 1.0J, at least about 1.5 J, 
at least about 2.0J, at least about 2.5 J, at least about 3.0J, at 
least about 3.5 J, at least about 4.0J, or at least about 4.5J). In 
Some embodiments, the amount of energy imparted to the 
continuous phase by the size reduction process is about 5.0J 
or less (e.g., about 4.5J or less, about 4.0J or less, about 3.5 
J or less, about 3.0J or less, about 2.5J or less, about 2.0J or 
less, about 1.5J or less, about 1.0J or less, about 0.5J or less, 
about 0.1 J or less, about 0.05 J or less, about 0.01 J or less, 
about 0.005 J or less, or about 0.001 J or less). 
The amount of energy imparted to the continuous phase by 
the size reduction process can range from any of the minimum 
values described above to any of the maximum values 
described above. For example, the amount of energy imparted 
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to the continuous phase by the size reduction process can 
range from about 0.0005 J to about 5J (e.g., from about 0.005 
J to about 3 J). 
In some embodiments, the method for reducing the size of 
the molten droplets includes mixing using a Hobart-type 
mixer or other mixer which includes rotating paddles, arms, 
or blades. The mixer using rotating paddles, arms, or blades 
can employ a speed of rotation for the paddles, arms, or blades 
in the range of about 500 to about 1,200 rpm for varying 
periods of time (e.g., mixing times ranging from 30 seconds 
to 30 minutes). In some embodiments, reducing the size of the 
molten droplets comprises low shear mixing. The mixing can 
involve a shear rate of at least about 10 reciprocal seconds 
(e.g., at least about 50 reciprocal seconds, at least about 100 
reciprocal seconds, at least about 200 reciprocal seconds, at 
least about 250 reciprocal seconds, at least about 300 recip 
rocal seconds, at least about 400 reciprocal seconds, at least 
about 500 reciprocal seconds, at least about 600 reciprocal 
seconds, at least about 700 reciprocal seconds, at least about 
750 reciprocal seconds, at least about 800 reciprocal seconds, 
or at least about 900 reciprocal seconds). The mixing can 
involve a shear rate of about 1000 reciprocal seconds or less 
(e.g., about 900 reciprocal seconds or less, about 800 recip 
rocal seconds or less, about 750 reciprocal seconds or less, 
about 700 reciprocal seconds or less, about 600 reciprocal 
seconds or less, about 500 reciprocal seconds or less, about 
400 reciprocal seconds or less, about 300 reciprocal seconds 
or less, about 250 reciprocal seconds or less, about 200 recip 
rocal seconds or less, about 100 reciprocal seconds or less, or 
about 50 reciprocal seconds or less). 
The mixing can involve a shear rate ranging from any of the 
minimum values described above to any of the maximum 
values described above. For example, the mixing can involve 
a shear rate ranging from about 10 reciprocal seconds to about 
1000 reciprocal seconds (e.g., from about 50 reciprocal sec 
onds to about 500 reciprocal seconds, or from about 50 recip 
rocal seconds to about 250 reciprocal seconds). 
In certain embodiments, a second poorly water soluble 
bioactive agent is added to the aqueous Suspension, to the 
Superheated continuous phase, or combinations thereof. The 
second poorly water Soluble bioactive agent can have a higher 
melting point than the first poorly water soluble bioactive 
agent. The aqueous Suspension can be heated to a temperature 
greater than the melting point of both the first and the second 
poorly water soluble bioactive agent. Alternatively, the aque 
ous Suspension can be heated to a temperature ranging from 
the melting point of the first poorly water soluble bioactive 
agent to less than the melting point of the second poorly water 
soluble bioactive agent. In these embodiments, molten drop 
lets of the first poorly water soluble bioactive agent serve as a 
solvent in which the second poorly water soluble bioactive 
agent is dissolved or dispersed. In certain cases, the second 
poorly water soluble bioactive agent dissolves in the molten 
droplets of the first poorly water soluble bioactive agent, and 
step (b) comprises cooling the molten droplets to form 
micronized particles comprising the first poorly water soluble 
bioactive agent and the second poorly water soluble bioactive 
agent. In other cases, the second poorly water Soluble bioac 
tive agent becomes dispersed in the molten droplets of the 
first poorly water Soluble bioactive agent, and step (b) com 
prises cooling the molten droplets to form micronized par 
ticles comprising the first poorly water soluble bioactive 
agent and the second poorly water soluble bioactive agent. 
By way of example, a first poorly water soluble bioactive 
agent (e.g., ibuprofen; melting point of 75° C.) may be sus 
pended in water and heated to a temperature of from about 














standard pressure to about 1,000 psi to form a superheated 
continuous phase comprising molten droplets of ibuprofen. 
Ciprofloxacin can be added to the aqueous Suspension of 
ibuprofen or to the Superheated continuous phase. Ciprof 
loxacin melts with decomposition at approximately 250° C. 
and thus is not amenable to melt processing; however, cipro 
floxacin dissolves in the molten droplets of ibuprofen. The 
molten droplets can then be cooled to form micronized par 
ticles comprising a homogeneous mixture of ibuprofen and 
ciprofloxacin. This methodology can be used to prepare 
micronized particles for the co-delivery of multiple bioactive 
agents with a co-controlled release profile. 
The aqueous Suspension can comprise water, Ringer's 
solution, phosphate buffered saline (PBS), or isotonic sodium 
chloride solution. If desired, the aqueous Suspension can fur 
ther comprises an excipient. Representative excipients 
include solvents, diluents, pH modifying agents, preserva 
tives, antioxidants, Suspending agents, wetting agents, vis 
cosity modifiers, tonicity agents, stabilizers, and combina 
tions thereof. Suitable pharmaceutically acceptable 
excipients are preferably selected from materials which are 
generally recognized as safe (GRAS), and may be adminis 
tered to an individual without causing undesirable biological 
side effects or unwanted interactions. 
In variations of the processes described above, the poorly 
water soluble bioactive agent can be melted prior to addition 
to the aqueous phase. Thus, also provided are processes for 
preparing micronized particles comprising a poorly water 
soluble bioactive agent which comprise (a) melting the poorly 
water soluble bioactive agent, (b) introducing the melted 
poorly water soluble bioactive agent into a Superheated aque 
ous phase heated to a temperature of from about 100° C. to 
about 280° C. at a pressure of from greater than standard 
pressure to about 1,000 PSI to form a superheated continuous 
phase comprising molten droplets of the poorly water soluble 
bioactive agent dispersed in Superheated water, and (c) cool 
ing the molten droplets to form micronized particles compris 
ing the poorly water soluble bioactive agent. In certain 
embodiments, step (b) comprises a Superheated aqueous 
phase heated to a temperature ranging from the melting point 
of the poorly water soluble bioactive agent to 20° C. higher 
than the melting point of the poorly water soluble bioactive 
agent (e.g., heated to a temperature ranging from the melting 
point of the poorly water soluble bioactive agent to 10° C. 
higher than the melting point of the poorly water soluble 
bioactive agent). 
Introducing the melted poorly water soluble bioactive 
agent into the Superheated aqueous phase can comprise 
injecting droplets of the melted poorly water soluble bioac 
tive agent into the Superheated aqueous phase. Injecting drop 
lets of the melted poorly water soluble bioactive agent into the 
Superheated aqueous phase can comprise spraying the melted 
poorly water soluble bioactive agent into the superheated 
aqueous phase. Injecting droplets of the melted poorly water 
soluble bioactive agent into the Superheated aqueous phase 
can comprise extruding the melted poorly water soluble bio 
active agent into the Superheated aqueous phase. For 
example, the melted poorly water Soluble bioactive agent can 
be extruded into the Superheated aqueous phase through a 
microporous membrane (i.e., membrane emulsification). In 
certain embodiments, the Superheated aqueous phase is flow 
ing orthogonally to the Surface of the microporous membrane 
during extrusion of the melted poorly water soluble bioactive 
agent into the Superheated aqueous phase (i.e., cross-flow 
membrane emulsification). 
In variations of the processes described above, a matrix 
material and a poorly water Soluble bioactive agent are added 
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to the aqueous phase. These processes can be used to form 
micronized particles comprising a mixture of a matrix mate 
rial and a poorly water soluble bioactive agent. Thus, also 
provided are processes for preparing micronized particles 
comprising a poorly water soluble bioactive agent that can 
comprise (a) heating an aqueous Suspension comprising a 
matrix material and the poorly water soluble bioactive agent 
to a temperature of from about 100° C. to about 280° C. at a 
pressure of from greater than standard pressure to about 1,000 
PSI to form a Superheated continuous phase comprising mol 
ten droplets of the matrix material dispersed in superheated 
water, and (b) cooling the molten droplets to form micronized 
particles comprising the matrix material and the poorly water 
soluble bioactive agent. In certain embodiments, step (a) 
comprises heating the aqueous Suspension to a temperature 
ranging from the melting point of the matrix material to 10° 
C. higher than the melting point of the matrix material. 
Any suitable matrix material can be used. The matrix mate 
rial can be, for example, a polymer, wax, or lipid which 
provides for the controlled release of the poorly water soluble 
bioactive agent. Examples of Suitable matrix materials 
include cellulosic polymers such as hydroxypropyl cellulose, 
hydroxyethyl cellulose, hydroxymethyl cellulose, hydrox 
ypropyl methyl cellulose, hydroxypropyl methyl cellulose 
acetate Succinate, hydroxypropylmethyl cellulose phthalate, 
methylcellulose, ethyl cellulose, cellulose acetate, cellulose 
acetate phthalate, cellulose acetate trimellitate and car 
boxymethylcellulose sodium; acrylic acid polymers and 
copolymers, preferably formed from acrylic acid, meth 
acrylic acid, methyl acrylate, ethyl acrylate, methyl meth 
acrylate and/or ethyl methacrylate, and other methacrylic 
resins that are commercially available under the tradename 
Eudragit(R) (Rohm Pharma; Westerstadt, Germany), including 
Eudragit R. L30D-55 and L100-55 (soluble at pH 5.5 and 
above), Eudragit(R) L-100 (soluble at pH 6.0 and above), 
Eudragit(R) S (soluble at pH 7.0 and above, as a result of a 
higher degree of esterification), and Eudragits(R NE, RL and 
RS (water-insoluble polymers having different degrees of 
permeability and expandability); Vinyl polymers and copoly 
mers such as polyvinyl pyrrolidone, vinyl acetate, vinylac 
etate phthalate, vinylacetate crotonic acid copolymer, and 
ethylene-Vinyl acetate copolymer; enzymatically degradable 
polymers such as azo polymers, pectin, chitosan, amylose and 
guargum; Zein; shellac; alginic acid; poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid)-poly 
ethyleneglycol (PLA-PEG) block copolymers, polyanhy 
drides, poly(ester anhydrides), ppolyglycolide (PGA), poly 
3-hydroxybutyrate (PHB) and copolymers thereof, poly-4- 
hydroxybutyrate (P4HB), polycaprolactone, waxes, such as 
spermaceti, beeswax, and carnuba wax, long chain lipid mix 
tures, such as gelucires (i.e., polyethylene glycol glycerides 
composed of mono-, di- and triglycerides and mono- and 
diesters of PEG), lauroyl macrogol-32 glycerides, lauroyl 
polyoxyl-32 glycerides, and lauroyl polyoxylglycerides, long 
chain alcohols, such as cetyl alcohol, long chain fatty acids, 
Such as behinic acid, and combinations thereof. 
The poorly water soluble bioactive agent can have a higher 
melting point than the matrix material. The aqueous Suspen 
sion can be heated to a temperature greater than the melting 
point of both the matrix material and the poorly water soluble 
bioactive agent. Alternatively, the aqueous Suspension can be 
heated to a temperature ranging from the melting point of the 
matrix material to less than the melting point of the poorly 
water soluble bioactive agent. In these embodiments, molten 
droplets of the matrix material can serve as a solvent in which 
the poorly water soluble bioactive agent is dissolved or dis 













agent dissolves in the molten droplets of the matrix material, 
and step (b) comprises cooling the molten droplets to form 
micronized particles comprising the first poorly water soluble 
bioactive agent and the second poorly water soluble bioactive 
agent. In other cases, the poorly water Soluble bioactive agent 
becomes dispersed in the molten droplets of the matrix mate 
rial, and step (b) comprises cooling the molten droplets to 
form micronized particles comprising the first poorly water 
soluble bioactive agent and the second poorly water soluble 
bioactive agent. 
Once formed by any of the processes described above, the 
micronized particles can be dried using methods known in the 
art. Drying the micronized particles can involve separating 
the micronized particles from the aqueous phase in which 
they are dispersed. Drying the micronized particles can 
involve further drying the separated micronized particles to 
reduce residual water content of the micronized particles. In 
certain cases, the micronized particles are dried, meaning that 
the micronized particles have a water content ranging from 
0% by weight to about 5% by weight, based on the total 
weight of the micronized particles. For example, dried 
micronized particles can have a water content of about 5% or 
less by weight, based on the total weight of the micronized 
particles (e.g., about 4% or less by weight, about 3% or less by 
weight, about 2% or less by weight, about 1% or less by 
weight, or about 0.5% or less). In some embodiments, the 
micronized particles have a water content ranging from about 
0.1% by weight to about 3% by weight, based on the total 
weight of the micronized particles (e.g., from about 0.1% by 
weight to about 2% by weight, or from about 0.1% by weight 
to about 1% by weight). Suitable methods for drying the 
micronized particles include spray drying (including steam 
drying), lyophilizing, filtration, or combinations thereof. In 
certain embodiments, the micronized particles are dried by 
spray drying. 
Once formed, the micronized particles can be stabilized. 
Stabilizing the micronized particles can comprise contacting 
the micronized particles with a stabilizer, Such as a Surfactant, 
polymer, or combination thereof. Examples of suitable stabi 
lizers include include natural Surfactants, such as casein, 
gelatin, tragacanth, waxes, enteric resins, paraffin, acacia, 
gelatin, cholesterol esters and triglycerides; nonionic Surfac 
tants such as polyoxyethylene fatty alcohol ethers, Sorbitan 
fatty acid esters, polyoxyethylene fatty acid esters, Sorbitan 
esters, glycerol monostearate, polyethylene glycols, cetyl 
alcohol, cetostearyl alcohol, Stearyl alcohol, poloxamers, 
polaxamines, methylcellulose, ethylcellulose, hydroxycellu 
lose, hydroxy propylcellulose, hydroxy propylmethylcellu 
lose, noncrystalline cellulose, polyvinyl alcohol, polyvi 
nylpyrrolidone, and synthetic phospholipids; anionic 
Surfactants such as potassium laurate, triethanolamine Stear 
ate, sodium lauryl Sulfate, alkyl polyoxyethylene Sulfates, 
Sodium alginate, dioctyl sodium Sulfo Succinate, negatively 
charged phospholipids (phosphatidylglycerol, phosphatidyl 
inosite, phosphatidylserine, phosphatidic acid and their 
salts), and negatively charged glyceryl esters, sodium car 
boxymethylcellulose, and calcium carboxymethylcellulose; 
cationic Surfactants such as quaternary ammonium com 
pounds, benzalkonium chloride, cetyltrimethylammonium 
bromide, chitosans and lauryldimethylbenzylammonium 
chloride; colloidal clays Such as bentonite and Veegum; and 
combinations thereof. 
If desired, the micronized particles can be coated with a 
controlled release material to modulate dissolution of the 
micronized particles. Suitable controlled release materials 
are known in the art, and include cellulosic polymers such as 
hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxym 
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ethyl cellulose, hydroxypropyl methyl cellulose, hydrox 
ypropyl methyl cellulose acetate Succinate, hydroxypropyl 
methyl cellulose phthalate, methylcellulose, ethyl cellulose, 
cellulose acetate, cellulose acetate phthalate, cellulose 
acetate trimelitate and carboxymethylcellulose sodium; 
acrylic acid polymers and copolymers, preferably formed 
from acrylic acid, methacrylic acid, methyl acrylate, ethyl 
acrylate, methyl methacrylate and/or ethyl methacrylate, and 
other methacrylic resins that are commercially available 
under the tradename Eudragit(R) (Rohm Pharma; Westerstadt, 
Germany), including Eudragit(R) L30D-55 and L100-55 
(soluble at pH 5.5 and above), EudragitR) L-100 (soluble at 
pH 6.0 and above), Eudragit(R) S (soluble at pH 7.0 and above, 
as a result of a higher degree of esterification), and 
Eudragits(R NE, RL and RS (water-insoluble polymers hav 
ing different degrees of permeability and expandability); 
vinyl polymers and copolymers such as polyvinyl pyrroli 
done, vinyl acetate, vinylacetate phthalate, vinylacetate cro 
tonic acid copolymer, and ethylene-Vinyl acetate copolymer; 
enzymatically degradable polymers such as azo polymers, 
pectin, chitosan, amylose and guargum; Zein; shellac; alginic 
acid; poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) 
(PLGA), poly(lactic acid)-polyethyleneglycol (PLA-PEG) 
block copolymers, polyanhydrides, poly(ester anhydrides), 
ppolyglycolide (PGA), poly-3-hydroxybutyrate (PHB) and 
copolymers thereof, poly-4-hydroxybutyrate (P4HB), poly 
caprolactone, waxes, such as spermaceti, beeswax, and car 
nuba wax, long chain lipid mixtures, such as gelucires (i.e., 
polyethylene glycol glycerides composed of mono-, di- and 
triglycerides and mono- and diesters of PEG), lauroyl mac 
rogol-32 glycerides, lauroyl polyoxyl-32 glycerides, and lau 
royl polyoxylglycerides, long chain alcohols, such as cetyl 
alcohol, long chain fatty acids, such as behinic acid, and 
combinations thereof. 
The resulting micronized particles can be amorphous or 
crystalline. In some embodiments, the micronized particles 
are Substantially free of organic solvents. In some embodi 
ments, the micronized particles are monodisperse in size. A 
population of particles can be said to be monodisperse when 
the particles in the population have the same or nearly the 
same particle size. The term monodisperse can refer to par 
ticle distributions in which 90% of the distribution lies within 
5% of the average particle size. The average particle size 
refers to the statistical mean particle size (diameter) of the 
particles in a population of particles. The diameter of an 
essentially spherical particle can refer to the physical or 
hydrodynamic diameter. The diameter of a non-spherical par 
ticle can refer to the largest linear distance between two points 
on the Surface of the particle. The average particle size can be 
measured using methods known in the art, Such as dynamic 
light scattering. 
In some embodiments, the micronized particles prepared 
using the processes described herein have an average particle 
size of at least about 50 nm (e.g., at least about 200 nm, at least 
about 300 nm, at least about 400 nm, at least about 500 nm, at 
least about 600 nm, at least about 700 nm, at least about 800 
nm, at least about 900 nm, at least about 1 micron, at least 
about 2 microns, at least about 3 microns, at least about 4 
microns, at least about 5 microns, at least about 6 microns, at 
least about 7 microns, at least about 8 microns, at least about 
9 microns, at least about 10 microns, at least about 15 
microns, at least about 20 microns, at least about 25 microns, 
at least about 30 microns, at least about 35 microns, at least 
about 40 microns, at least about 45 microns, at least about 50 
microns, or at least about 55 microns). In some embodiments, 
the micronized particles prepared using the processes 













microns or less (e.g., about 55 microns or less, about 50 
microns or less, about 45 microns or less, about 40 microns or 
less, about 35 microns or less, about 30 microns or less, about 
25 microns or less, about 20 microns or less, about 15 microns 
or less, about 10 microns or less, about 9 microns or less, 
about 8 microns or less, about 7 microns or less, about 6 
microns or less, about 5 microns or less, about 4 microns or 
less, about 3 microns or less, about 2 microns or less, about 1 
micron or less, about 900 nm or less, about 800 nm or less, 
about 700 nm or less, about 600 nm or less, about 500 nm or 
less, about 400 nm or less, about 300nm or less, about 200 nm. 
or less, or about 100 nm or less). 
The micronized particles prepared using the processes 
described herein can have an average particle size ranging 
from any of the minimum values described above to any of the 
maximum values described above. For example, the micron 
ized particles prepared using the processes described herein 
can have an average particle size ranging from about 50 nm to 
about 60 microns (e.g., from about 50 nm to about 1 micron, 
from about 1 micron to about 5 microns, or from about 1 
micron to about 20 microns 
The particle size and particle size distribution of the result 
ing micronized particles can be selected in view of the desired 
therapeutic application. For example, in certain embodi 
ments, the micronized particles comprise a poorly water 
soluble bioactive agent for the treatment, prevention, or diag 
nosis of a pulmonary disease or disorder, Such as asthma or 
cystic fibrosis. In these embodiments, the particle size and 
particle size distribution of the micronized particles can be 
selected to facilitate pulmonary delivery. 
The respiratory tract is the structure involved in the 
exchange of gases between the atmosphere and the blood 
stream. The respiratory tract encompasses the upper airways, 
including the oropharynx and larynx, followed by the lower 
airways, which include the trachea followed by bifurcations 
into the bronchi and bronchioli. The upper and lower airways 
are called the conducting airways. The terminal bronchioli 
then divide into respiratory bronchioli which then lead to the 
ultimate respiratory Zone, the alveoli, or deep lung, where the 
exchange of gases occurs. 
The alveolar surface area is the largest in the respiratory 
system and is where drug absorption occurs. The alveoli are 
covered by a thin epithelium without cilia or a mucus blanket 
and secrete surfactant phospholipids. Effective delivery of 
therapeutic agents via pulmonary routes requires that the 
active agent be formulated so as to reach the alveoli. 
Particle morphology affects the depth of penetration of a 
particle into the lung, as well as uptake of the bioactive agent 
particle once delivered to the lung. For the treatment, preven 
tion, or diagnosis of many pulmonary diseases or disorders, 
drug particles should reach the alveoli to maximize therapeu 
tic efficacy. Accordingly, the micronized particles can be 
selected to have the appropriate mass median aerodynamic 
diameter (MMAD), tap density, and surface roughness to 
achieve delivery of the one or more active agents to the deep 
lung. Preferred particle morphologies for delivery to the deep 
lung are known in the art, and are described, for example, in 
U.S. Pat. No. 7,052,678 to Vanbever, et al. 
“Mass Median Aerodynamic Diameter” (MMAD), as used 
herein, refers to the median aerodynamic size of a plurality of 
particles. The “aerodynamic diameter is the diameter of a 
unit density sphere having the same settling Velocity, gener 
ally in air, as a powder and is therefore a useful way to 
characterize an aerosolized powder or other dispersed par 
ticle or particle formulation in terms of its settling behavior. 
The aerodynamic diameter encompasses particle or particle 
shape, density, and physical size of the particle or particle. 
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MMAD can be experimentally determined by methods 
known in the art, such as by cascade impaction. 
“Tap Density', as used herein, refers to a measure of the 
density of a powder, Such as a population of micronized 
particles. Tap density can be determined using the method of 5 
USP Bulk Density and Tapped Density, United States Phar 
macopia convention, Rockville, Md., 10th Supplement, 
4950-4951, 1999. Features which can contribute to low tap 
density include irregular Surface texture and porous structure. 
Particles having a mass median aerodynamic diameter 10 
(MMAD) of greater than about 5 microns generally do not 
reach the lung; instead, they tend to impact the back of the 
throat and are swallowed. Particles having diameters of about 
3 to about 5 microns are Small enough to reach the upper- to 
mid-pulmonary region (conducting airways), but may be too 15 
large to reach the alveoli. Smaller particles, (i.e., about 0.5 to 
about 3 microns), are capable of efficiently reaching the 
alveolar region. Particles having diameters Smaller than about 
0.5 microns can also be deposited in the alveolar region by 
sedimentation, although very Small particles may be exhaled. 20 
The precise particle size range effective to achieve delivery 
to the alveolar region will depend on several factors, includ 
ing the tap density of particles being delivered. Generally 
speaking, as tap density decreases, the MMAD of particles 
capable of efficiently reaching the alveolar region of the lungs 25 
increases. Therefore, in cases of particles with low tap den 
sities, particles having diameters of about 3 to about 5 
microns, about 5 to about 7 microns, or about 7 to about 9.5 
microns can be efficiently delivered to the lungs. A suitable 
aerodynamic diameter for maximum deposition within the 30 
lungs can be calculated. See, for example, U.S. Pat. No. 
7,052,678 to Vanbever, et al. 
In some embodiments, the micronized particles comprise a 
population of particles having a median mass aerodynamic 
diameter from about 0.5 to about 10 microns (e.g., from about 35 
0.5 microns to about 7 microns, or from about 0.5 to about 5 
microns). In some embodiments, the micronized particles 
comprise a population of particles having a median mass 
aerodynamic diameter from about 0.5 to about 3 microns. In 
Some embodiments, the micronized particles comprise a 40 
population of particles having a median mass aerodynamic 
diameter from about 3 to about 5 microns. In some embodi 
ments, the micronized particles comprise a population of 
particles having a median mass aerodynamic diameter from 
about 5 to about 7 microns. In some embodiments, the 45 
micronized particles comprise a population of particles hav 
ing a median mass aerodynamic diameter from about 7 to 
about 9.5 microns. 
In some cases, there may be an advantage to delivering 
particles larger than about 3 microns in diameter. Phagocyto- 50 
sis of particles by alveolar macrophages diminishes precipi 
tously as particle diameter increases beyond about 3 microns. 
Kawaguchi, H., et al., Biomaterials 7: 61-66 (1986); Krenis, 
L. J. and Strauss, B., Proc. Soc. Exp. Med., 107: 748-750 
(1961); and Rudt, S, and Muller, R. H., J. Contr. Rel, 22: 55 
263-272 (1992). By administering particles with an aerody 
namic Volume greater than 3 microns, phagocytic engulfment 
by alveolar macrophages and clearance from the lungs can be 
minimized. 
In some embodiments, at least about 80% (e.g., at least 60 
about 85%, at least about 90%, or at least about 95%) of the 
micronized particles in the population of particles have aero 
dynamic diameter of less than about 10 microns (e.g., less 
than about 7 microns, or less than about 5 microns). In some 
embodiments, at least about 80% (e.g., at least about 85%, at 65 
least about 90%, or at least about 95%) of the micronized 
particles in the population of particles have aerodynamic 
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diameter greater than about 0.5 microns. In some embodi 
ments, at least about 80% (e.g., at least about 85%, at least 
about 90%, or at least about 95%) of the micronized particles 
in the population of particles have aerodynamic diameter 
greater than about 0.1 microns. 
In some embodiments, at least about 80% (e.g., at least 
about 85%, at least about 90%, or at least about 95%) of the 
micronized particles in the population of particles have aero 
dynamic diameterranging from about 0.5 microns to about 10 
microns (e.g., from about 0.5 microns to about 7 microns, 
from about 0.5 microns to about 5 microns). In some embodi 
ments, at least about 80% (e.g., at least about 85%, at least 
about 90%, or at least about 95%) of the micronized particles 
in the population of particles have aerodynamic diameter 
ranging from about 0.5 microns to about 3 microns. In some 
embodiments, at least about 80% (e.g., at least about 85%, at 
least about 90%, or at least about 95%) of the micronized 
particles in the population of particles have aerodynamic 
diameter ranging from about 3 microns to about 5 microns. In 
Some embodiments, at least about 80% (e.g., at least about 
85%, at least about 90%, or at least about 95%) of the micron 
ized particles in the population of particles have aerodynamic 
diameter ranging from about 5 microns to about 7 microns. In 
Some embodiments, at least about 80% (e.g., at least about 
85%, at least about 90%, or at least about 95%) of the micron 
ized particles in the population of particles have aerodynamic 
diameter ranging from about 7 microns to about 9.5 microns. 
In some embodiments, the micronized particles can have a 
tap density of less than about 0.4 g/cm (e.g., less than about 
0.25 g/cm, or less than about 0.1 g/cm). Features which can 
contribute to low tap density include irregular Surface texture 
and porous structure. In some cases, the micronized particles 
are spherical or ovoid in shape. The micronized particles can 
have a Smooth or rough surface texture. 
Also provided are pharmaceutical formulations including 
micronized particles prepared using the processes described 
herein. Pharmaceutical formulations can include micronized 
particles in combination with one or more pharmaceutically 
acceptable excipients. Representative excipients include Sol 
vents, diluents, pH modifying agents, preservatives, antioxi 
dants, Suspending agents, wetting agents, viscosity modifiers, 
tonicity agents, stabilizing agents, and combinations thereof. 
Suitable pharmaceutically acceptable excipients are prefer 
ably selected from materials that are generally recognized as 
safe (GRAS), and may be administered to an individual with 
out causing undesirable biological side effects or unwanted 
interactions. The micronized particles can beformulated for a 
variety of routes of administration and/or applications. Suit 
able routes of administration include enteral, parenteral, pull 
monary, and topical. 
Suitable oral dosage forms include tablets, capsules, Sus 
pensions, syrups, and lozenges. Tablets can be made using 
compression or molding techniques well known in the art. 
Gelatin or non-gelatin capsules can prepared as hard or soft 
capsule shells, which can encapsulate liquid, Solid, and semi 
Solid fill materials, using techniques well known in the art. 
Oral dosage forms, such as capsules, tablets, and Suspensions, 
can for formulated for controlled release (e.g., immediate 
release, delayed release, extended release, pulsatile release, 
and combinations thereof) using methods known in the art. 
The micronized particles can also be formulated for 
parenteral administration. Parenteral administration refers to 
administration by any method other than through the diges 
tive tract or non-invasive topical or regional routes. For 
example, parenteral administration can include administra 
tion to a patient intravenously, intradermally, intraperito 
neally, intrapleurally, intratracheally, intramuscularly, Subcu 
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taneously, by injection, and by infusion. Parenteral 
formulations can be prepared as aqueous compositions using 
techniques is known in the art. Typically, Such compositions 
can be prepared as injectable formulations, such as, for 
example, particle Suspensions; Solid forms suitable for using 
to prepare Suspensions upon the addition of a reconstitution 
medium prior to injection; emulsions, such as water-in-oil 
(w/o) emulsions, oil-in-water (ofw) emulsions, and micro 
emulsions thereof, liposomes, or emulsomes. 
The carrier can be a solvent or dispersion medium contain 
ing, for example, water, ethanol, one or more polyols (e.g., 
glycerol, propylene glycol, and liquid polyethylene glycol), 
oils, such as Vegetable oils (e.g., peanut oil, corn oil, Sesame 
oil, etc.), and combinations thereof. The proper fluidity can be 
maintained, for example, by the use of a coating, such as 
lecithin, by the maintenance of the required particle size in the 
case of dispersion and/or by the use of Surfactants. In many 
cases, it will be preferable to include isotonic agents, for 
example, Sugars or sodium chloride. The parenteral formula 
tions described herein can be formulated for controlled 
release including immediate release, delayed release, 
extended release, pulsatile release, and combinations thereof. 
In certain embodiments, the micronized particles can be 
formulated as Suspension for injection to the eye. Pharmaceu 
tical formulations for ocular administration are preferably in 
the form of a sterile aqueous solution or Suspension of par 
ticles formed from one or more polymer-drug conjugates. 
Acceptable solvents include, for example, water, Ringer's 
solution, phosphate buffered saline (PBS), and isotonic 
sodium chloride solution. The formulation may also be a 
sterile Solution, Suspension, or emulsion in a nontoxic, 
parenterally acceptable diluent or solvent such as 1,3-butane 
diol. 
In some instances, the formulation is distributed or pack 
aged in a liquid form. Alternatively, formulations for ocular 
administration can be packed as a solid, obtained, for example 
by lyophilization of a suitable liquid formulation. The solid 
can be reconstituted with an appropriate carrier or diluent 
prior to administration. 
Solutions, Suspensions, or emulsions for ocular adminis 
tration may be buffered with an effective amount of buffer 
necessary to maintain a pH suitable for ocular administration. 
Suitable buffers are well known by those skilled in the art and 
Some examples of useful buffers are acetate, borate, carbon 
ate, citrate, and phosphate buffers. 
Solutions, Suspensions, or emulsions for ocular adminis 
tration may also contain one or more tonicity agents to adjust 
the isotonic range of the formulation. Suitable tonicity agents 
are well known in the art and some examples include glycerin, 
mannitol, Sorbitol, Sodium chloride, and other electrolytes. 
Solutions, Suspensions, or emulsions for ocular adminis 
tration may also contain one or more preservatives to prevent 
bacterial contamination of the ophthalmic preparations. Suit 
able preservatives are known in the art, and include polyhex 
amethylenebiguanidine (PHMB), benzalkonium chloride 
(BAK), stabilized oxychloro complexes (otherwise known as 
PuriteR), phenylmercuric acetate, chlorobutanol, sorbic acid, 
chlorhexidine, benzyl alcohol, parabens, thimerosal, and 
mixtures thereof. 
Solutions, Suspensions, or emulsions for ocular adminis 
tration may also contain one or more excipients known art, 
Such as dispersing agents, wetting agents, and Suspending 
agents. 
In certain embodiments, the micronized particles can be 
formulated for pulmonary administration. When formulated 
for pulmonary administration, the micronized particles can 













above. The micronized particles can be administered to the 
lungs as dry powder using Suitable methods known in the art 
(e.g., a dry powder inhaler). Alternatively, the micronized 
particles can be suspended in a liquid formulation, and 
administered to the lung using methods known in the art for 
the delivery of liquid formulations to the lungs (e.g., pressur 
ized metered dose inhaler, nebulizer, or electrohydrodynamic 
aerosol device). 
The processes described herein can also be utilized to 
prepare micronized particles of bioactive agents for non 
pharmaceutical uses. For example, the methods described 
herein can be utilized to prepare micronized particles of 
poorly water soluble agrichemicals, such as pesticides, which 
can be administered in agricultural settings. 
EXAMPLES 
Example 1 
Preparation of Ibuprofen Particles 
Tween(R) polysorbate 80 was dissolved/dispersed at a 0.05 
0.75% WIV concentration in distilled water. The mixture was 
then pre-heated to around melting point of Ibuprofen (-77° 
C.). Ibuprofen was then dispersed into the aqueous phase in 
an amount effective to achieve an ibuprofen concentration of 
between 0.05 and 1% W/V. The mixture was then Stirred 
under high heat until a pre-emulsion was formed. 
A pressure vessel lid was added to seal the reaction vessel, 
and the mixture was heated. Upon heating, the pressure inside 
the reaction vessel increased. The resultant increase in pres 
sure in the reaction vessel increased the boiling point of the 
aqueous phase. The mixture was stirred until mixture reached 
a temperature at which the viscosity of the dispersed oil phase 
(ibuprofen) was low enough to permit the molten ibuprofen 
droplets to be reduced in size with simple stirring (a pressure 
of approximately 25 psi and a corresponding temperature of 
approximately 116°C.). 
The molten droplets were subsequently cooled to form 
micronized ibuprofen particles. Micronized particles could 
be formed draining the molten emulsion through a cooling 
tube and/or flash cooled/diluted into a Surfactant-containing 
aqueous liquid. Micronized particles could also be formed by 
cooling the molten emulsion to room temperature under stir 
ring or under ice. 
Each of these methods yielded micronized ibuprofen par 
ticles with different characteristics. Flash/cooling and dilu 
tion resulted in partial dissolution of the ibuprofen, and 
formed micronized particles in the form of very fine needles. 
Cooling the molten emulsion to room temperature under stir 
ring or under ice afforded stable micro and nano-Suspensions 
of micronized ibuprofen particles. Samples were analyzed 
using a SympatacR) laser diffraction apparatus. The results of 
this analysis are shown in FIG. 1. 
Example 2 
Preparation of Ibuprofen--Ciprofloxacin Particles 
300 mg of ibuprofen was heated in a beaker under stirring 
to melt. Once molten, lecithin was added to the molten ibu 
profen to form a 0.01-5% W/V emulsion of lecithin in ibu 
profen. 200 mg ciprofloxacin was then added to the molten 
dispersion of ibuprofen and lecithin. Once a clear molten 
solution was formed, approximately 50 mL deionized water 
(preheated to 80°C.) was added to the mixture. The mixture 
was stirred at an elevated temperature until a homogenous 
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emulsion was formed. The emulsion was Subsequently 
cooled to room temperature, and lyophilized or centrifuged to 
retrieve micronized particles. 
Differential scanning calorimetry (DSC) was used to con 
firm the molten miscibility of ciprofloxacin and ibuprofen, as 
indicated by a depression and widening of the ciprofloxacin 
melting endotherm (from 255° C. to ~210°C.) in the presence 
of ibuprofen (melting endotherm at 77°C.) in a 2:3 physical 
mixture of ciprofloxacin/ibuprofen. See FIG. 2. Particle size 
analysis (laser diffraction analysis using a SympatacR) laser 
diffraction apparatus) was conducted on a resuspended lyo 
phylate of a 2:3 mixture of ciprofloxacin/ibuprofen. The 
results of this analysis are shown in FIG. 3. Particle size 
analysis revealed that a majority of the particles had a particle 
size below 1 micron. These results demonstrate the feasibility 
of utilizing a first drug having a lower melting point drug as a 
dissolution carrier or solvent for second drug having has a 
higher melting point. 
The processes and compositions of the appended claims 
are not limited in Scope by the specific processes and com 
positions described herein, which are intended as illustrations 
of a few aspects of the claims. Any processes and composi 
tions that are functionally equivalent are intended to fall 
within the scope of the claims. Various modifications of the 
processes and compositions in addition to those shown and 
described herein are intended to fall within the scope of the 
appended claims. Further, while only certain representative 
processes and compositions disclosed herein are specifically 
described, other combinations of the processes and composi 
tions also are intended to fall within the scope of the appended 
claims, even if not specifically recited. Thus, a combination of 
steps, elements, components, or constituents may be explic 
itly mentioned herein or less, however, other combinations of 
steps, elements, components, and constituents are included, 
even though not explicitly stated. 
The term “comprising and variations thereof as used 
herein is used synonymously with the term “including and 
variations thereof and are open, non-limiting terms. Although 
the terms “comprising and “including have been used 
herein to describe various embodiments, the terms “consist 
ing essentially of and "consisting of can be used in place of 
“comprising and “including to provide for more specific 
embodiments of the invention and are also disclosed. Other 
than where noted, all numbers expressing geometries, dimen 
sions, and so forth used in the specification and claims are to 
be understood at the very least, and not as an attempt to limit 
the application of the doctrine of equivalents to the scope of 
the claims, to be construed in light of the number of signifi 
cant digits and ordinary rounding approaches. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under 
stood by one of skill in the art to which the disclosed invention 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference. 
What is claimed is: 
1. A process for preparing micronized particles comprising 
a poorly water Soluble bioactive agent, the process compris 
ing 
(a) heating an aqueous Suspension comprising the poorly 
water soluble bioactive agent to a temperature of from 
about 100° C. to about 280° C. at a pressure of from 
greater than standard pressure to about 1,000 psi to form 
a Superheated continuous phase comprising molten 
droplets of the poorly water soluble bioactive agent dis 
persed in Superheated water, 
(b) reducing the size of the molten droplets while main 













ture of from about 100° C. to about 280° C. and a 
pressure of from greater than standard pressure to about 
1,000 psi, wherein reducing the size of the molten drop 
lets comprises a low energy process; and 
c) cooling the molten droplets to form micronized particles 
comprising the poorly water Soluble bioactive agent. 
2. The process of claim 1, wherein reducing the size of the 
molten droplets comprises low shear mixing. 
3. The process of claim 1, further comprising drying the 
micronized particles. 
4. The process of claim 1, further comprising stabilizing 
the micronized particles. 
5. The process of claim 1, wherein cooling the molten 
droplets comprises cooling the molten droplets at a rate effec 
tive to form micronized particles comprising a crystalline 
form of the poorly water soluble bioactive agent. 
6. The process of claim 1, wherein the micronized particles 
have an average particle size ranging from about 1 micron to 
about 5 microns. 
7. The process of claim 1, wherein the poorly water soluble 
bioactive agent has a solubility in water of about 5 mg/mL or 
less at 25° C. 
8. The process of claim 1, wherein the poorly water soluble 
bioactive agent has a melting point of from about 100° C. to 
about 280°C., and 
wherein step (a) comprises heating the aqueous Suspension 
to a temperature ranging from the melting point of the 
poorly water soluble bioactive agent to about 10° C. 
higher than the melting point of the poorly water soluble 
bioactive agent. 
9. The process of claim 1, further comprising adding a 
second poorly water Soluble bioactive agent to the aqueous 
Suspension, to the Superheated continuous phase, or combi 
nations thereof. 
10. The process of claim 9, wherein step (b) comprises a 
Superheated aqueous phase heated to a temperature ranging 
from the melting point of the first poorly water soluble bio 
active agent to less than the melting point of the second poorly 
water soluble bioactive agent. 
11. A process for preparing micronized particles compris 
ing a poorly water soluble bioactive agent, the process com 
prising 
(a) melting the poorly water soluble bioactive agent; 
(b) introducing the melted poorly water soluble bioactive 
agent into a Superheated aqueous phase heated to a tem 
perature of from about 100° C. to about 280° C. at a 
pressure of from greater than standard pressure to about 
1,000 psi to form a Superheated continuous phase com 
prising molten droplets of the poorly water soluble bio 
active agent dispersed in Superheated water, and 
(c) cooling the molten droplets to form micronized par 
ticles comprising the poorly water soluble bioactive 
agent. 
12. The process of claim 11, wherein introducing the 
melted poorly water soluble bioactive agent into the super 
heated aqueous phase comprises injecting droplets of the 
melted poorly water soluble bioactive agent into the super 
heated aqueous phase. 
13. The process of claim 12, wherein injecting droplets of 
the melted poorly water soluble bioactive agent into the 
Superheated aqueous phase comprises spraying the melted 
poorly water soluble bioactive agent into the superheated 
aqueous phase. 
14. The process of claim 12, wherein injecting droplets of 
the melted poorly water soluble bioactive agent into the 
Superheated aqueous phase comprises extruding the melted 
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poorly water soluble bioactive agent into the superheated 
aqueous phase through a microporous membrane. 
15. The process of claim 14, wherein injecting droplets of 
the melted poorly water soluble bioactive agent into the 
Superheated aqueous phase comprises cross-flow membrane 
emulsification. 
16. A process for preparing micronized particles compris 
ing a poorly water soluble bioactive agent, the process com 
prising 
(a) heating an aqueous suspension comprising a matrix 
material and the poorly water soluble bioactive agent to 
a temperature of from about 100° C. to about 280° C. at 
a pressure of from greater than standard pressure to 
about 1,000 psi to form a superheated continuous phase 
comprising molten droplets of the matrix material dis 
persed in superheated water, and 
(b) cooling the molten droplets to form micronized par 
ticles comprising the matrix material and the poorly 
water soluble bioactive agent. 
17. The process of claim 16, wherein the poorly water 
Soluble bioactive agent has a higher melting point than the 
matrix material, and wherein step (a) comprises heating the 
aqueous suspension to a temperature ranging from the melt 
ing point of the matrix material to less than the melting point 
of the poorly water soluble bioactive agent. 
18. The process of claim 16, wherein the matrix material 





and wherein step (a) comprises heating the aqueous suspen 
Sion to a temperature ranging from the melting point of the 
matrix material to about 10° C. higher than the melting point 
of the matrix material. 
19. A process for preparing micronized particles compris 
ing a poorly water soluble bioactive agent, the process com 
prising 
(a) heating an aqueous suspension comprising the poorly 
water soluble bioactive agent to a temperature of from 
about 100° C. to about 280° C. at a pressure of from 
greater than standard pressure to about 1,000 psi to form 
a Superheated continuous phase comprising molten 
droplets of the poorly water soluble bioactive agent dis 
persed in superheated water; 
(b) adding a second poorly water soluble bioactive agent to 
the aqueous suspension, to the superheated continuous 
phase, or combinations thereof; and 
(c) cooling the molten droplets to form micronized par 
ticles comprising the poorly water soluble bioactive 
agent. 
20. The process of claim 19, wherein step (a) comprises a 
Superheated aqueous phase heated to a temperature ranging 
from the melting point of the first poorly water soluble bio 
active agent to less than the melting point of the second poorly 
water soluble bioactive agent. 
